• Bioverativ, Bicycle Therapeutics to Jointly Develop New Therapies for Rare Blood Disorders
  • Catalyst’s CB 2679d Was Shown to Outperform BeneFix in Phase 1/2 Trial in Hemophilia B
  • Transitions: Teaching Our Young Adults to Manage Their Care
  • Regenxbio Likely to Add Dimension’s DTX201 for Hemophilia A to Its Pipeline
  • How Our Family Regained Control
  • Alnylam Suspends All Trials of Fitusiran After Hemophilia A Patient Dies in Phase 2 Study
  • Bayer Asks FDA to Approve BAY94-9027, Long-acting Treatment for Hemophilia A
  • Inhibitors and Blood Work: No Fear of Numbers
  • Bioverativ to Partner with Invicro on Ultrasound Imaging of Hemophilia Joint Disease
  • Shire and MicroHealth Working on App to Improve Care of Hemophilia Patients Resistant to Treatment
  • Bullies, the Bus, and Warriors: Reminders of Magnificence
  • Pfizer Debuts Innovative Video Game and Wristband for Children with Hemophilia